Endovascular intervention has become a well-recognized treatment modality for peripheral artery disease; however, midand long-term outcomes have been plagued by limited durability. Plain balloon angioplasty and bare-metal stents have historically suffered from high restenosis rates leading to the need for frequent repeat revascularization procedures. The innovation of locally administered, drug-delivering balloons and stents has been a direct result of technological innovations directed toward prevention and treatment of this limitation. Over the last 5 years, numerous clinical trials investigating the use of drug-coated stents and drug-coated balloons indicate a significant improvement in endovascular treatment durability and outcomes. This review provides an up-to-date assessment of the current evidence for the use of drug-coated stents and drug-coated balloons in the treatment of femoropopliteal and infrapopliteal peripheral artery Company; has received consulting/speaking honoraria from Gilead, St. Jude Medical, Cordis, Boehinger Ingelheim, SanofiAventis, and Medtronic; has ownership through his spouse of Mdcare Global; and has intellectual property in HygeiaTel. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Karan Sarode and David Spelber contributed equally to this paper.
, show superior short-and mid-term increased patency and freedom from target lesion revascularization (TLR) for DCS and DCB in the treatment of infrapopliteal and femoropopliteal PAD (5) (6) (7) (8) (9) (10) . This review provides an overview of the development of drug-eluting technology in PAD and highlights ongoing clinical trials and promising new technologies.
Historically, restenosis after endovascular therapy for PAD has been a major limitation for BMS and PTA (11) . The principal mechanism of restenosis for both PTA and BMS is thought to be neointimal hyperplasia due to mechanical injury of the vessel wall (12) . And, in the setting of increased biomechanical stress at the femoropopliteal territory, BMS implantation leads to higher rates of in-stent restenosis when used to treat PAD versus coronary artery disease (13) . The advent of drug-eluting technology and other technologies such as cutting balloons, atherectomy, and cryoplasty have been a direct result of the desire to decrease restenosis rates.
Restenosis rates are tied to anatomic distribution of PAD, which is itself correlated with disease severity. Critical limb ischemia (CLI), which represents 1% to 2% of PAD and is defined by rest pain, nonhealing or poorly healing ulcers, or gangrene, is the most severe form (14) . CLI is associated with longsegment femoropopliteal lesions, multilevel disease, and diffuse infrapopliteal lesions (15) . Higher restenosis rates for diffuse, infrapopliteal disease and longer lesions have been borne out by multiple recent studies (16, 17) (18) . Sirolimus also blocks vascular smooth muscle cell migration and proliferation by arresting the cell at the G1-S checkpoint-a point in the cell cycle that does not cause cell death (19) . Both drugs are lipophilic, which enhances tissue uptake; however, determining and efficiently delivering an optimal dose remains a challenge. Drug densities used on DCB are generally higher than those used on DCS because the amount of time available for drug transfer is significantly less with balloon inflation than it is with stent implantation (20) .
DCS TECHNOLOGY
A typical DCS consists of 3 elements: a scaffold manufactured using different kinds of metals (such as nickel-titanium, platinum-chromium, or stainless steel), a polymer matrix (consisting of silicone, cellulose esters, and polyurethane), and the drug itself. The drug elutes at a rate proportional to degradation of the polymer matrix, the latter being of particular importance because it has been shown to cause inflammatory responses and late-onset restenosis. Although most first-generation DCS used the polymer coating to control drug elution, newer-generation stents coat the drug directly onto the outer surface of the stent strut without using a polymer (21) . To combat the problem of thrombogenic and 
inflammatory responses, a variety of bioabsorbable materials such as polyesters, polycarbonates, bacterial-derived polymers, and corrodible metals have recently been incorporated into stent design both as the polymer coating and also as the stent scaffold itself (22).
TRIALS COMPARING DCS WITH BMS IN FEMOROPOPLITEAL DISEASE
Studies evaluating DCS in PAD are summarized in Table 2 , at 24-month follow-up, Duplex ultrasound-derived in-stent restenosis and TLR rates did not differ significantly between patients treated with SES and BMS. This lack of superior efficacy of SES has been attributed to 2 reasons: 1) lower than expected restenosis rates in the BMS group, probably due to shorter lesion lengths (mean 8.3 cm); 2) a "late catch-up" effect, attributed, in part, to an inflammatory response toward the degraded SES polymer matrix (23, 24) .
Everolimus, a newer sirolimus analogue, shares much of the same immunosuppressive and antiproliferative effects as sirolimus, but is more lipophilic and is more rapidly absorbed into the vessel wall (25) The ZILVER-PTX (Evaluation of the Zilver PTX Drug-Eluting Peripheral Stent) RCT (n ¼ 479) compared the efficacy of paclitaxel-eluting stents (PES) with PTA (primary randomization) and BMS (secondary randomization) in patients with femoropopliteal stenosis over 2 years. The Zilver PTX had higher event-free survival than did PTA and BMS, and also had higher patency rates than did the provisional BMS group, at up to 36 months (3, 27) . To date, the Zilver PTX is the only DCS to have U.S. Food and Drug Administration approval for use during peripheral artery interventions. 
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Infrainguinal Drug Delivering Technology Along with other SES trials, the PARADISE trial was included in a 2013 meta-analysis (Yang et al. [9] ), which pooled outcomes for 16 combined RCTs and non-RCTs comparing DCS, BMS, and PTA in infrapopliteal disease in a total of 3,780 patients ( Table 1) .
The meta-analysis showed that primary BMS im- however, the study has been discontinued due to insufficient enrollment (33) .
DCS CONCLUSIONS
Overall, DCS improves mid-term (<2 year) outcomes in femoropopliteal and BTK lesions, reducing restenosis and increasing limb salvage rates. Whereas the 36-month results of Zilver PTX are promising, additional data from the aforementioned and forthcoming trials are necessary to determine whether peripheral DCS will be as impactful as they have been in coronary arteries. DCS may prove to be most useful in shorter BTK lesions (<100 mm), as smaller caliber peripheral vessels may respond similarly to the coronary arteries.
Unfortunately, BTK disease and CLI are typically associated with longer lesion length and consequently an increase in difficulty and cost in treatment (9) .
The question of whether SES or PES is more effective remains unanswered. Some researchers have suggested that limus-based drugs may have superior outcomes due to fewer late thrombotic complications, as paclitaxel requires 90 days for endothelialization compared with 30 days for sirolimus (19) . A 2009 metaanalysis (Biondi-Zoccai et al. [7] ) of 18 mostly nonrandomized trials (n ¼ 640) examined the efficacy of provisional stenting with BMS, SES, and PES in
Sarode et al. Table 3 and currently ongoing studies are listed in Table 4 . There is increasing evidence supporting the superiority of DCB over PTA for the treatment of femoropopliteal and BTK artery disease. Tables 1 and 2 . (6) FREEWAY (62) Percentage of stenosis (12) ADCAT (65) Tables 1 to 3 .
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Sarode et al. Two studies (DEBATE-BTK and Schmidt et al. [17] )
have thus far shown promising outcomes for long 
